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Ulrica Forsl€ow,1 Jonas Mattsson,2,3 Thomas Gustafsson,4 Mats Remberger2,3Bronchiolitis obliterans (BO) is a serious pulmonary complication after allogeneic hematopoietic stem cell
transplantation (HSCT). The aim of this study was to evaluate the diagnostic methods used, the incidence
of BO, risk factors, and outcome in patients with BO at our center. The study included 527 HSCT patients
transplanted between 1995 and 2003. Lung function tests (n 5 1177) and risk factor analyses were per-
formed in all patients. Chest X-rays and high-resolution tomographies were investigated in patients with
BO. The incidence of BO was 4.8%, as the diagnosis was established in 25 patients (4 children). Median
time between HSCTand diagnosis of BOwas 356 (84-1823) days. Eight patients (32%) had radiologic changes
consistent with BO. Forced expiratory volume for 1 second (FEV1) and forced expiratory flow at 50% (FEF50)
and 75% (FEF75) of forced vital capacity (FVC) produced median values that were 49%, 25%, and 18% of the
reference values at the time of BO diagnosis. FEF75 was reduced before BO diagnosis in 7 patients (28%). In
a multivariate risk factor analysis, chronic graft-versus-host disease (cGVHD) was found to be associated
with BO (P\.001), whereas donor lymphocyte infusion (DLI) diminished the risk (P5 .02). For 10 patients
with late BO (.1 year after HSCT), 80% survived 5 years after diagnosis, compared to 38% survival in 15
patients with early-onset BO (P 5 .06). We conclude that lung function tests with a persistent decrease in
FEV1 were more important than radiographic methods to recognize and monitor BO, that FEF75 may serve
as an early warning of BO, and that late-onset BO appears to be associated with better outcome. Chronic
GVHD was confirmed as a risk factor, and administration of DLI may diminish the risk.
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Allogeneic hematopoietic stem cell transplantation
(HSCT) has become a widely accepted treatment for
malignancies and lymphohematopoietic failure syn-
dromes. Despite the advances in histocompatibility
matching, new and better treatments for infectious
complications, and better immunosuppressive drug
treatments, pulmonary complications have continued
to be common and often lethal [1-4]. Bronchiolitis
obliterans (BO) is a serious, noninfectious pulmonary1Division of Respiratory Medicine and Allergology,
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6/j.bbmt.2010.12.701disorder associated with a poor prognosis [1-3,5]. The
underlying pathogenic mechanisms are poorly
understood, and the etiology remains obscure (1,3).
The most important factor associated with BO has
been shown to be the presence of chronic graft-versus-
host disease (cGVHD) [6-9]. BO is histologically
characterized by obliteration of the lumen of the
respiratory bronchioles by organizing granulation
tissue, infiltration of mononuclear cells, or fibrosis,
and clinically by persistent, progressive obstruction of
air flow [1,3,5,10]. In this retrospective single-center
study, we determined the incidence of BO, risk factors,
and outcome in HSCT recipients who developed this
complication, and we evaluated the use of radiology
and pulmonary function tests to establish the diagnosis.PATIENTS AND METHODS
Patients and Donors
Between January 1995 and December 2003, 527
patients underwent allogeneic HSCT at Karolinska
University Hospital, Huddinge. Seventy-seven pa-
tients died within 120 days of HSCT, and 102 patients
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other countries or because of the lack of lung function
tests. In the remaining 330 patients, a total of 1177 lung
function tests were performed. For these 330 patients,
all spirometries were carefully studied and re-evaluated
by an experienced physiologist and a lung specialist.
Patients with spirometries showing no or minimal air
flow obstruction with normal or nearly normal forced
expiratory volume for 1 second (FEV1), forced expira-
tory flow at 50% (FEF50), and 75% (FEF75) valueswere
regarded as non-BO cases. Patients with mild, moder-
ate, or severe obstruction of air flow (FEV1 66%-80%,
51%-65%, or #50%) [1,11] were investigated
concerning clinical findings and radiographic,
pathologic, and laboratory data. Cases that did not
fulfill the National Institutes of Health (NIH) criteria
for BO [12] were then screened as non-BO cases.
There were 295 male patients and 232 female pa-
tients, with a median age of 34 years (range:\1 to 77).
Most patients had malignancies (n5 471), mainly acute
leukemia (n5 242) or chronic leukemia (n5 110). Do-
nors were anHLA-identical sibling or related individualTable 1. Characteristics of Patients Who Underwent Allogeneic H
2003, According to Whether or Not They Developed Bronchiolitis O
All Patients
Diagnosis n 5 527
Nonmalignant disorder 56
Acute leukemia 242
Chronic leukemia 110
Other malignancy 119
Disease stage (early/late) 259/229
Sex (M/F) 295/232
Age 34 (<1-77)
Donor
HLA-identical related 227
MUD 246
Mismatched 54
Donor sex (M/F) 305/220
Donor age 37 (0-71)
Stem cell source (BM/PBSCs) 280/247
NC dose (108/kg) 4.6 (0.03-80)
Female donor to male recipient 101 (19%)
G-CSF after HSCT 341 (65%)
Previous HSCT (auto/allo) 42 (8%)
Conditioning
MAC 417
TBI-based 266
Non-TBI 151
RIC 110
ATG 349 (66%)
GVHD prophylaxis
CsA + MTX 430 (82%)
CsA + MMF 45
Other 52
DLI treatment 126 (24%)
Acute GVHD II-IV 155 (29%)
Chronic GVHD 194 (37%)
Follow-up (years) 7.0 (3.2-12.1)
BM indicates bone marrow; PBSCs, peripheral blood stem cells; NC dose nucl
cell transplantation; MAC, myeloablative conditioning; TBI, total-body irradia
GVHD, graft-versus-host disease; CsA, cyclosporine A; MTX, methotrexate; M
Disease stage: early, CR1/CP1 (first complete remission/first chronic phase), o
-DRB1 matched unrelated donor.
*P 5 .05, ** P < .001.(n5 227), anHLA-A, -B, and -DRB1matchedunrelated
donor (MUD) (n5 246), or a mismatched related/unre-
lated donor (n5 54). Nonmalignant disorders included
severe aplastic anemia (SAA) (n5 23), Fanconi’s anemia
(FA) (n 5 5), paroxysmal nocturnal hemoglobinuria
(PNH) (n 5 2), and various inherited metabolic disor-
ders. Polymerase chain reaction (PCR) sequence-
specific primer (SSP) high-resolution typing was used
for both HLA class I and II antigens [13].
The study was approved by the ethics committee of
Karolinska Institutet (DNR 425/97). Characteristics
of donors and of patients with or without BO are given
in Table 1.
Conditioning and GVHD Prophylaxis
Myeloablative conditioning was administered to
417 patients and consisted of cyclophosphamide (Cy)
at 120 mg/kg in combination with 7.5-10 Gy
single-dose total-body irradiation (TBI) (n 5 172) or
fractionated (fTBI) 4  3 Gy (n 5 94) (TBI-based)
or busulfan (Bu) at 16 mg/kg (n 5 136). Ten patients
with SAA received Cy at 200 mg/kg, and 5 with FAematopoietic Stem Cell Transplantation in the Period 1995 to
bliterans (BO)
BO No BO
n 5 25 n 5 502
1 (4%) 55 (11%)
12 (48%) 230 (46%)
8 (32%) 102 (20%)
4 (16%) 115 (23%)
15/10 244/219
14/11 281/221
33 (6–64) 34 (<1-77)
12 (48%) 215 (43%)
11 (44%) 235 (47%)
2 (8%) 52 (10%)
12/13 293/207
37 (19-66) 37 (0-71)
10/15 270/232
8.5 (0.7-25.6) 4.6 (0.03-80)
6 (24%) 95 (19%)
20 (80%) 321 (64%)
3 (12%) 39 (8%)
23 (92%) 394 (78%)
13 (52%) 253 (50%)
10 (40%) 141 (28%)
2 (8%) 108 (22%)
14 (56%) 335 (67%)
23 (92%) 407 (81%)
0 45
2 (8%) 50
2 (8%) 124 (25%)*
7 (28%) 148 (30%)
22 (88%) 172 (34%) **
7.6 (3.2-11.0) 7.0 (3.2-12.1)
eated cell dose; G-CSF, granulocyte-colony stimulating factor; SCT, stem
tion; RIC, reduced-intensity conditioning; ATG, antithymocyte globulin;
MF, mycophenolate mofetil; DLI, donor lymphocyte infusion.
r nonmalignant disorder; late, beyond CR1/CP1; MUD, HLA-A-, -B-, and
1216 Biol Blood Marrow Transplant 17:1214-1221, 2011U. Forsl€ow et al.received fludarabine (FLU) and Cy. Reduced-intensity
conditioning (RIC) was given to 110 patients and con-
sisted of FLU at 30 mg/m2/day for 3 to 6 days in com-
bination with Cy at 60 mg/kg for 2 days (n5 19), Bu at
4 mg/kg/day for 2 days (n5 46), treosulfan at 12 to 14
g/m2/day for 3 days (n5 4), 2 Gy TBI (n5 34), or 2
3 Gy fTBI and Cy at 30 mg/m2 for 2 days (n5 7) [14].
Antithymocyte globulin (ATG) was given for 2 to 5
days before transplantation to all patients with unre-
lated or mismatched donors, or with a nonmalignant
disorder (n5 349) [15]. As GVHD prophylaxis cyclo-
sporine A (CsA), and methotrexate (MTX) were given
to the majority of patients (n5 430, 82%). During the
first month, blood CsA levels were kept at 100 ng/mL
when a sibling donor was used, and at 200 to 300 ng/
mL when an unrelated donor was used. In the absence
of GVHD, CsA was discontinued after 6 months for
patients with malignancies and after 24 months for pa-
tients with nonmalignant disorders.
Diagnosis and Treatment of GVHD
Acute GVHD (aGVHD) and cGVHD were diag-
nosed and graded on the basis of clinical symptoms
and/or biopsies (skin, liver, gastrointestinal tract, or
oral mucosa) according to standard criteria [16,17].
The patients were treated for grade I aGVHD with
prednisolone, starting at 2 mg/kg/day, which was
tapered after the initial response. Chronic GVHD
was initially treated with CsA and steroids.
Additional Treatment
Donor lymphocyte infusions (DLIs) were adminis-
tered to 126 patients (24%) because of relapse (n5 62),
increasing chimerism (n 5 41), graft failure (n 5 16),
posttransplant lymphoproliferative disorder (PTLD)
(n 5 2), or as prophylactic treatment in patients with
high-risk leukemia (n 5 5). A median of 2 (range:
1-11) doses was given. The escalations in doses were
done in steps of 0.5 to 1 log, starting between 1 
105 to 1  106 CD31 cells/kg, depending on the
type of donor, the degree of HLA match, and the his-
tory of GVHD in the recipient. DLI doses were given
at approximately 4-week intervals until response or
GVHD. First DLI was given at a median of 167 days
(range: 23-1973) after HSCT.
Granulocyte colony-stimulating factor (G-CSF) (5
mg/kg/day) was given to all patients from day 10 after
HSCT until neutrophil engraftment (.0.5  109/L)
between April 1997 and August 2001. After that date,
prophylactic G-CSF was not given because we found
that there was an increased risk of aGVHD of grades
II-IV with this drug.
Definition of BO
In this study, we followed the clinically diagnostic
criteria for BO according to the NIH consensus docu-ment [12].We defined BO as a severe pulmonary com-
plication affecting the small airways, characterized by
the onset of new airflow obstruction following alloge-
neic HSCT. Patients who developed BO within 1 year
of HSCT were defined as having an early BO, and
those who developed BO after 1 year were defined as
having a late BO.The diagnosis required identification
of pulmonary symptoms not explained by an infection,
such as dry cough and dyspnea combined with a persis-
tent reduction in FEV1 in pulmonary function tests by
$20% from baseline or FEV1\75% of that predicted,
FEV1/FVC\0.7 and residual volume (RV) .120%,
radiographic changes consistent with BO, or patho-
logical confirmation of constrictive bronchiolitis
[7,12,18].Diagnostic Methods
Spirometries were performed before transplanta-
tion, then approximately every 3 to 6 months during
the first 2 years, and then at least once a year. Where
there were respiratory symptoms such as dry cough
or dyspnoea not explained by an infection, additional
spirometries were conducted. FEV1 and FVC,
FEV1/FVC ratio, FEF at 50% of FVC (FEF50), and
FEF at 75% of FVC (FEF75) were also registered, as
well as RV, total lung capacity (TLC), and diffusing
lung capacity (DLC). FEF50 and FEF75 values repre-
sent maximal expiratory flow measured at points
when 50% or 75% of the FVC has been expired.
Before transplantation, the majority of the patients
had chest X-rays. Posttransplantation chest X-rays and
high-resolution computed tomography (HRCT) was
only performed when there were respiratory symp-
toms. In BO patients, chest X-rays are often normal.
HRCTmay, however, showmultilobular areaswith di-
minished attenuation and perfusion and/or air trapping
at full expiration. Bronchiectasies (dilated and thick-
ened bronchi) and areas of scarring may also be found.
Sometimes a mosaic pattern is seen because of reduced
perfusion to areas with obstruction and redistribution
of the blood to normal areas [19,20]. However,
previous studies have shown that radiographic
findings in BO patients following HSCT and lung
transplantation may be inconsistent and of limited
accuracy [19,21].
In a few cases, bronchoalveolar lavage (BAL) was
performed as a consequence of GVHD engaging the
lungs. Otherwise, BAL was performed if an infection
was suspected in BO patients. Video-assisted thoraco-
scopic surgical lung biopsies or transbronchial biopsies
(TBBs) were not obtained because BO is often a
patchy peripheral disease, a condition that makes it dif-
ficult to obtain an adequate biopsy sample [5,11], and
because of the risk of bleeding and pneumothorax in
these fragile and often thrombocytopenic patients
[22,23].
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The incidences of BO were estimated with cumu-
lative incidence curves, taking competing events into
consideration and compared by Gray’s test. The com-
peting event was death without BO. Patients with in-
complete follow-up were censored at the time of last
contact. Univariate and multivariate risk factor analy-
ses were performed using the proportional subdistri-
bution hazard regression model developed by Fine
and Gray. Factors with P values of#.10 in the univar-
iate analyses were introduced into the stepwise-
elimination multivariate analyses. To study the effects
of chronic GVHD and DLI as time-dependent vari-
ables, multivariate analysis was also performed using
Cox proportional hazards model including time-
dependent variables. Analysis was performed using
the cmprsk package (developed by Gray, June 2001),
Splus 6.2 software (Insightful, Seattle, WA), and Sta-
tistica software (StatSoft, Tulsa, OK). The Mann-
Whitney U test was used to compare continuous
variables and the chi-square method was used to com-
pare the distribution of categoric variables.RESULTS
General Data on Patients with BO
The cumulative incidence of BO in the 527 patients
was 4.8%: 25 patients developed BO between 1995 and
2003. Median age was 33 (6-64) years and 4 patients
(16%)were children aged 6 to 13 years (Table 1). Seven
patients (28%) were smokers or ex-smokers, and 14
(56%) had never smoked. Smoking data were unavail-
able for 4 patients. Median time from HSCT to devel-
opment of BO was 356 (84-1823) days. Acute GVHD
of grades I (n 5 11) and grades II-III (n5 7) occurred
in 18 (72%) of the patients who developed BO and
cGVHDin 22 (88%).The characteristics of theBOpa-
tients are given in Table 1.
Evaluation of Radiology and Spirometry in BO
Patients
HRCT (n 5 50) was performed median 2 (1-7)
times after HSCT in 22 of the 25 patients with BO.
Chest X-rays alone were performed in 3 patients.
However, in these patients, RV was 159%, 175%,
and 280%, respectively, which is why all of these 25 pa-
tients fulfilled the NIH criteria for BO despite the fact
that no HRCT was performed. In 8 of 25 patients
(32%), radiographic changes associated with BO
were seen: bronchiectasies with dilated and thickened
bronchi and areas of scarring (n 5 8) in combination
with air trapping and a mosaic pattern (n5 5). In total,
176 spirometries were performed a median of 7 (2-14)
times in these 25 patients. In 305 patients who, after
screening, were regarded as not having BO, 1001 spi-rometries (median 3.5 [2-11] per patient) were
performed. The FEV1 value at the time of BO
diagnosis was median 49% (23%-74%), which was
a decline from baseline (median 49% [24%-81%]).
The FEV1/FVC ratio was median 61% (35%-69%).
The median values of FEF50 and FEF75 were 25%
(6%-43%) and 18% (6%-48%) of predicted,
respectively. In 6 patients, FEF50 was reduced, and
in 7 patients, FEF75 was reduced already in the
spirometry preceding the 1 that—according to the
NIH criteria—established the diagnosis of BO. In
these patients, at least 2 (range: 2-12) spirometries
were performed before the diagnostic spirometry.
The decline between the preceding spirometry
and the 1 before was median 36% (23%-55%)
for FEF50 and median 29% (14%-81%) for FEF75.
The median value for RV was 177% (92%-363%) of
the reference values. In 2 patients, RV was\120%.
In 1 of these patients, HRCT findings were consistent
with BO, and in the other patient, a postmortem bi-
opsy confirmed the diagnosis of BO. TLC was median
97% (79%-138%), and DLC was median 59% (35%-
86%) in the 25 BO patients. The reduction in FEV1,
FVC, and FEF values was persistent in all patients.
The disease progression was variable, however; for
some patients, the majority with early BO, patients
had a rapid decline in lung function, whereas others,
mostly patients with late-onset BO, had a more pro-
tracted course (Figure 1A and 1B).Risk Factors and Incidences of BO
In the univariate analysis, 5 factors showed an asso-
ciation with BO at P values of #.10, and they were in-
troduced into the stepwise-elimination multivariate
analysis. These factors were hematologic malignancy
(hazard ratio [HR] 5.42, P 5 .10), myeloablative con-
ditioning (MAC) (3.46, P 5 .09), cGVHD (9.24, P\
.0001), no DLI treatment (4.18, P 5 .05), and receipt
of G-CSF after HSCT (2.51, P5 .065). Only cGVHD
(HR 9.83, 95% confidence interval [CI] 3.42-28.2, P
\ .0001) and DLI (0.18, 0.04-0.77, P 5 .02) were
found to be significantly associated with BO in the
multivariate analysis. When cGVHD and DLI
were treated as time-dependent variables and were
introduced into Cox proportional hazards model,
both factors were still found to be statistically signif-
icant (cGVHD 2.50, 1.55-4.02, P\ .001) and (DLI
0.50, 0.26-0.94, P 5 .03). The cumulative incidences
of BO in patients with DLI treatment (n 5 126) or
without DLI treatment (n 5 401) were 1.6% and
6.6%, respectively, and they were 11.4% and 1.1%
in patients with and without cGVHD. The inci-
dences of BO in patients with and without these
risk factors are shown in Figure 2. Only 2 patients
developed BO after DLI treatment; both received
only 1 dose of DLI.
Figure 1. Forced expiratory flow at 75% (FEF75) of forced vital capacity
(FVC) (A) and forced expiratory volume in 1 second (FEV1) (B) in pa-
tients with early-onset bronchiolitis obliterans (BO) (within 1 year of
allogeneic HSCT) and late-onset BO. Median and 25% to 75% quartile
range.
Figure 2. Cumulative incidences of bronchiolitis obliterans (BO) with
and without the risk factors chronic graft-versus-host disease (cGVHD)
and treatment with donor lymphocyte infusion (DLI).
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As immunosuppressive treatment after HSCT,
CsA and MTX were administered to all of the 25 pa-
tients with BO. Before the diagnosis of BO, CsA had
been administered a median of 5.5 (2-12) months to
15 patients with early BO, and a median of 13.5
(4-60) months to 10 patients with late BO. Because
of GVHD, steroids had been administered to patients
with early BO amedian of 5.5 (0-12) months before the
diagnosis of BO, and after establishment of the diagno-
sis, they were continued, increased, or initiated in all of
these patients. For a 5-year follow-up time after the di-
agnosis, CsA was given for amedian of 8 (0-60) months
to 13 of 15 patients with early BO, and for a median of
43 (0-60) months to 8 of 10 patients with late BO.
Likewise, steroids were administered for a median of
12 (0.5-49) months to those with early BO, but only
to 4 of the 10 patients with late BO for a median of
54.5 (22-60) months. Other therapies used for patients
with early and late BO were, respectively, cimetidine
(n5 14 and n5 8), omeprazole (n5 1 and n5 2), an-
ticholinergics, bronchodilators, and/or inhaled ste-roids (n 5 13 and n 5 9), psoralen and ultraviolet
light A therapy (PUVA) (n 5 6 and n 5 6), mycophe-
nolate mofetil (MMF) (n 5 3 and n 5 1) for 5, 12, 20,
and 24 months, tacrolimus and sirolimus (n 5 1 and
n5 3) for 3, 24, 36, and 37 months, or the IL-2 antag-
onist daclizumab (n 5 1 and n 5 3). In patients with
early BO, FEV1 was median 57% (37%-74%) and
FEV1/FVC was 62% (35%-82%) at the time of diag-
nosis of BO. In the spirometry preceding the NIH di-
agnostic spirometry, FEV1 was 95% (59%-112%) and
FEV1/FVC was 83% (65%-100%). In patients with
late BO, FEV1 was median 42% (23%-60%) and
FEV1/FVC was median 59% (36%-67%) at the time
of diagnosis of BO, whereas in the preceding spirome-
try, FEV1 was median 89% (64%-102%) and FEV1/
FVC was median 78% (66%-93%). The NIH criteria
for BOwere not fulfilled in any of the spirometries pre-
ceding the NIH diagnostic spirometry.
Outcome in BO Patients
Eleven patients with BO (44%) died, 7 of them be-
cause of BO in combination with cGVHD and/or in-
fection. The overall 5-year survival in patients with
BO (n5 25) was 64%, compared to 50% in those with-
out BO (n5 502). Survival 5 years after diagnosis of BO
was 38% and 80% in patients with early BO (within 1
year of HSCT, n 5 15) and late BO (n 5 10) BO, re-
spectively (P5 .06) (Figure 3). In patients with or with-
out DLI treatment, survival at 5 years was 35% and
55% (P5 .005). The 5-year survival for patients treated
with DLI because of chimerism, relapse, and graft fail-
ure was 65%, 20%, and 17%, respectively.Median sur-
vival after DLI treatment was 416 (2-4280) days.DISCUSSION
The reported incidence of BO is inconsistent, be-
cause uniform diagnostic criteria have yet to be estab-
lished; the reported incidence range is 0% to 48%
Figure 3. Overall survival (OS) after diagnosis of bronchiolitis obliter-
ans (BO) in patients with early-onset BO (within 1 year of HSCT) and
late-onset BO.
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son for thewide differences in incidencemay be that the
term BO has been applied to different histopathologic
patterns of bronchiolar fibrosis as well as various clini-
cal syndromes ranging froman irreversible disease with
progressive air flow obstruction (BO) to bronchiolitis
obliterans organizing pneumonia (BOOP), an infiltra-
tive, acute, and reversible process associated with
restricted lung volume [10,25]. Although BO may be
a noninfectious disorder, it still complicates a variety
of pulmonary infections [26,27]. Viral infections,
particularly adenovirus and parainfluenzavirus,
have been frequently implicated [26-28]. No viral
infections preceded the BO diagnosis in this study,
but 4 patients had had culture-verified bacterial infec-
tions that may have initiated the process.
According to the NIH consensus document of cri-
teria for cGVHD, 1 of the criteria for BO is evidence of
air trapping or small airway thickening, bronchiecta-
sies on HRCT, RV .120%, or pathologic confirma-
tion of constrictive bronchiolitis [12]. In our study,
repeated HRCTs were performed in 22 of the 25 BO
patients. Only 8 patients (32%) had radiologic changes
inHRCTs, associated with BO.Despite the poor diag-
nostic value of HRCTs in our study, the NIH criteria
were met, because in 23 of 25 cases, RV was .120%,
and in 2 other patients, HRCT and pathological
findings confirmed the diagnosis. The NIH consensus
document also states that the only diagnostic manifes-
tation of cGVHD is biopsy-proven BO [12]. However,
adequate lung biopsies are difficult to achieve before
death and may result in severe complications in up to
13% of patients with cGVHD and BO [18,22,23].
Instead, in our study, persistent dyspnea and dry
cough in the absence of infection at the very time of
diagnosis of BO, and a new onset of reduced lung
function monitored by spirometries, established the
diagnosis. In the literature, and according to the
NIH criteria, the most relevant spirometric criteriaof BO following allogeneic HSCT, as well as
after lung transplantation, appears to be a .20%
reduction in FEV1 from pretransplantation or
baseline values, or FEV1 \75% of the predicted
value with FEV1/FVC \0.7 [7,9,11,29]. In this
study, in which lung function tests from 330 patients
were thoroughly evaluated, the patients diagnosed
with BO fulfilled all of these criteria.
In this study, dynamic spirometries and lung volume
tests were performed in all BO patients. Lung volume
tests can, however, be difficult to perform sometimes,
for instance, in children and inpatientswith an impaired
performance status. Thus, we believe that FEV1 is the
most reliable and easy way to detect and monitor the
way BO develops, which is in accordance with previous
findings [18]. Furthermore, some studies on lung-
transplanted patients have suggested that a reduction
in FEF of between 25% and 75% of FVCmay precede
the decline in FEV1 [30-32]. In this study, 7 patients
(28%)—in whom at least 2 (2-12) spirometries were
performed before BO was diagnosed, and who were
monitored by spirometry every 3 to 6 months for at
least 2 years and then annually—had a reduced FEF75
even before the NIH spirometry criteria for BO were
fulfilled. The FEF values depend on the lung volume
and are sensitive (but nonspecific) indicators of
subsequent development of BO, and should therefore
be interpreted with caution. Even so, regular
monitoring of FEF50 and FEF75 and intraindividual
comparisons of the FEF values may serve as an early
warning of BO [32].
Even though the incidence of GVHD and air flow
obstruction has been reduced after the introduction of
CsA as GVHD prophylaxis [33], and lower incidences
of BO have been reported after RIC compared to after
myeloablative conditioning [34], efforts to treat BO
have been disappointing. In the univariate analysis,
we found an association between RIC and less BO
(relative humidity [RH] 3.46, P5 .09), but this associ-
ation did not hold in the multivariate analysis. Some
studies have suggested that the use of statins or
maintenance macrolide therapy may have a role in
the treatment of BO [35-37], as they may halt the
disease progression. Furthermore, GVHD-associated
esophagitis with recurrent aspirations has also been
taken into account as a possible cause of BO [1]. After
establishment of the diagnosis of BO, all 25 patients
in our study received antacids, and 22 (88%) received
oral steroids, anticholinergics, bronchodilators, and/
or inhaled steroids. Bronchodilators have been shown
to affect clinical improvement and to increase FEV1
values [3]. In this study, we found that in 13 patients
(52%), treatment with (especially) oral or inhaled
steroids may have contributed to an increased (n 5 4)
or at least temporarily stabilized (n5 9) FEV1. Eleven
of these patients are still alive. Treatment with
PUVA, tacrolimus, and IL-2 antagonists may also
1220 Biol Blood Marrow Transplant 17:1214-1221, 2011U. Forsl€ow et al.have been of some benefit, because 5 of the 12 pa-
tients who received PUVA (all 4 patients who re-
ceived tacrolimus and 3 of the 4 who received IL-2
antagonist) are still alive.
It is well known that BO is associated with consid-
erable mortality [7,18,38,39]. However, there is some
published evidence that some patients may develop
a more slowly progressing or temporarily reversible
disease [7,38]. When comparing early and late BO,
we found that the mortality was higher in those with
early BO (60%) than in those with late BO (20%).
The 5-year survival for patients with early-onset BO
in our study was nearly the same as in other studies
[18,38], but it was high for those with late-onset BO.
One explanation of the better outcome in patients
with late-onset BO could be their better immune com-
petence after more than a year compared to the first
few months after HSCT [40]. Furthermore, patients
with late-onset BO had had a more protracted treat-
ment with CsA and steroids at the time of diagnosis
than patients with early-onset BO (CsA for a median
of 13.5 versus 5.5 months and steroids for a median
of 12 versus 5.5 months). However, regardless of
whether they had late or early onset, the survivors
ended up with equally poor lung function. There was
no significant difference in treatment regimens or
time from diagnosis of BO to start of steroids and other
treatments in these cohorts.
In the multivariate risk factor analyses, cGVHD
was significantly associated with development of BO
(P\ .001) and occurred in 88% of the patients with
BO, compared to 34% inpatientswithoutBO.Chronic
GVHD has also been found to be a risk factor for BO
in several other studies. However, in most of these
studies, cGVHD was combined with other risk factors
[6,9,38,39,41-43]. Instead, we found a negative
correlation between DLI treatment and BO. DLI has
been shown to clear pre-existing infections or to
protect from development of new infections [44]. Our
study suggests that DLI may also protect against BO
even though this is a noninfectious disease. One possi-
ble explanation of the unexpected protective role of
DLI could be that DLI treatment changes the cytokine
profile towards a Th1 profile, which is different from
the Th2 profile believed to occur in cGVHD. Still,
a protective role for DLI in BO may be controversial
and speculative. For example, patients may die early af-
ter DLI; however, in this study, only 30 (24%) of the
patients given DLI died within 3 months of DLI, and
67 patients (53%) survived more than 1 year after
DLI. Further studies with larger patient material are
needed to determine the possible influence of a protec-
tive role of DLI.
We believe that future studies should concentrate
on trying to explore the underlying etiological mecha-
nisms of BO in order to diagnose the condition as soon
as possible and to find adequate treatment regimens.One factor that has been suggested to have potential
importance for an early diagnosis is Clara cell 16-
kDa secretory protein (CC16) [45]. Low or decreasing
levels of CC16 (by more than 40% compared to previ-
ous samples) have been found to be associated with de-
velopment of BO [45]. A better understanding of
allograft pathogenesis could hopefully lead to an im-
proved ability to predict the likelihood of progression
of BO in individual recipients, and thereby help to de-
cide the best possible intervention for each patient.
This strategy will hopefully avoid potentially toxic
multidrug therapies.
To summarize, BO is a serious, progressive disease
associated with a high mortality, especially if it occurs
within 1 year of HSCT. The most important diagnos-
tic and monitoring factor was found to be FEV1, but
FEF values may also be of benefit to alert the clinicians
to perform a more careful follow-up. Chronic GVHD
is a well-known risk factor, but unexpectedly, DLI
treatment may have a protective role.ACKNOWLEDGMENTS
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